AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

IDEAYA Biosciences Inc. (IDYA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.65

0.99 (4.79%)

At close: Feb 20, 2025, 3:59 PM

21.73

0.37%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	17
Market Cap	1.87B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.36
PE Ratio (ttm)	-6.44
Forward PE	n/a
Analyst	Buy

Ask	22.68
Volume	512,210
Avg. Volume (20D)	956,327
Open	20.74
Previous Close	20.66
Day's Range	20.70 - 21.96
52-Week Range	19.96 - 47.72
Beta	undefined

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 23, 2019

Employees 124

Stock Exchange NASDAQ

Ticker Symbol IDYA

Website https://www.ideayabio.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 144.80% from the latest price.

Buy 92.31%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

IDEAYA Biosciences Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+0.34%

IDEAYA Biosciences shares are trading higher after... Unlock content with Pro Subscription

7 months ago

-3.37%

IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.

News

1 week ago · zacks.com

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

1 week ago · zacks.com

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.

1 week ago · seekingalpha.com

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uv...

1 week ago · zacks.com

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead can...